ClinicalTrials.gg
CompletedNCT04626414Updated Aug 24, 2025Results posted

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

A Phase 1 interventional study of Ferric maltol capsule and Ferric maltol suspension in Anemia, Iron Deficiency, sponsored by Shield Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Shield Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.

Enrollment
10th of 12
32 · median 78
Started
2020
the only one that year
Phase 1
2 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
7 of 12
Shield Therapeutics

Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 8th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →

About ferric maltol

ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing ferric maltol in Anemia, Iron-Deficiency as a file.
02

Study summary

The purpose of the study is to compare the Pharmacokinetics (PK) of the new ferric maltol suspension, in adults, with the existing ferric maltol capsule.

Read the detailed description

Open-label, Phase 1, four way crossover study to compare the PK of the new ferric maltol suspension, in healthy volunteers, with the existing ferric maltol capsules under fed and fasted conditions.

32 subjects will be randomised to 1:1:1:1 ratio to receive one of the treatment sequences.

Based on the randomised sequence, subjects will receive a single dose of 30mg ferric maltol capsule in a fed/ fasted condition and 30 mg (5ml) ferric maltol suspension in a fed/ fasted condition.

Subject participation in the study will consist of 3 periods:

  1. Screening: up to 14 days
  2. Randomised treatment: 8 days
  3. Post-treatment follow up: 3-7 days following drug discontinuation
03

Conditions studied

  • Anemia, Iron Deficiency

Keywords

  • iron deficiency, anaemia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following criteria must be met for a subject to participate in the study:

  1. Must voluntarily sign and date each Institutional Review Board (IRB)-approved form (ICF) prior to the initiation of any screening or study-specific procedures.
  2. Willing and able to comply with study requirements.
  3. Healthy adult subjects 18 to 55 years of age, inclusive at the time of informed consent.
  4. (BMI) of 18-32 kg/m2 inclusive
  5. Female subjects of must not be planning a pregnancy or be pregnant or lactating. All female subjects must have a negative result for the pregnancy tests performed at screening and each treatment period.
  6. Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as hormonal contraception (oral, implants, injection, ring, or patch) and intrauterine contraceptive devices (IUDs), at least 3 months prior to Screening, or a vasectomized partner.

    Note: complete abstinence from sexual intercourse is an acceptable form of contraceptive practice.

  7. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral, tubal ligation, bilateral salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or , defined as spontaneous amenorrhea for at least 2 years
  8. Male subjects with partners of childbearing potential must have had surgical sterilization (vasectomy) at least 26 weeks prior to Screening or use a male barrier method of contraception (i.e. male condom with spermicide) during any sexual intercourse from Study Day -1 (beginning of confinement) until 3 months after the Follow-up Visit.

    Note: Complete abstinence from sexual intercourse is an acceptable form of contraceptive practice.

  9. Male subjects must agree to abstain from sperm donation from initial study drug administration through 3 months after administration of the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria is not eligible for participation in the study.

  1. Known or allergy to the active substance or of Ferric maltol oral suspension or capsules;
  2. Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurological, or psychiatric disease, as determined by the Investigator;
  3. Presence or history of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines;
  4. Recent (within 6 months of screening) history of drug or alcohol abuse;
  5. Positive screen results for drugs of abuse, alcohol at screening or Study Day -1 of Period1;
  6. Consumption of alcohol within 72 hrs prior to study drug administration;
  7. Positive test result for surface antigen (HBSaAg), virus antibody (HCV Ab), or antibody (HIV Ab) at screening;
  8. Donation or loss of 550 mL or more blood volume or receipt of a transfusions of any blood product within 8 weeks prior to study drug administration and 14 days for plasma donation unless medically inadvisable;
  9. Use of any over the counter medications, including herbal product within 7 days prior to Screening until study completion. Except for ordinary pain (e.g. headache), some analgesics (mainly paracetamol) and which have no drug interactions with the study products may be given;
  10. Has received within 28 days prior to Screening intramuscular or intravenous (IV) injection or administration of depot iron preparation;
  11. Has received oral iron supplementation within 7 days prior to Screening;
  12. Has concomitant disease that would significantly compromise iron absorption or absorbed iron utilization such as swallowing disorders, gastric pH-disturbance and/or extensive small bowel resection;
  13. Scheduled or expected hospitalization and/or surgery during the course of the study;
  14. Diagnosed to be COVID-19 positive by polymerase chain reaction testing (SARS-CoV-2-RTPCR positive) of a respiratory specimen (preferably a nasopharyngeal swab) on Day -2;
  15. Participation in any other interventional clinical study within 28 days prior to Screening;
  16. Any other unspecified reason that, in the opinion of the Investigator or the Sponsor makes the subject unsuitable for enrolment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    30 mg ferric maltol capsule in a fed condition

    Single dose of 30 mg ferric maltol capsule in a fed condition

    Drug: Ferric maltol capsule

  • Active comparator
    30 mg ferric maltol capsule in a fasted condition

    Single dose of 30 mg ferric maltol capsule in a fasted condition

    Drug: Ferric maltol capsule

  • Experimental
    30 mg (5 ml) ferric maltol suspension in a fed condition

    Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition

    Drug: Ferric maltol suspension

  • Experimental
    30 mg (5 ml) ferric maltol suspension in a fasted condition

    Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition

    Drug: Ferric maltol suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition

    Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension.

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fasted condition

  2. Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition

    Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fed condition

  3. Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fasted Condition

    Ratio of area under the curve (AUClast) of total serum iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fasted condition

  4. Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fed Condition

    Ratio of area under the curve (AUClast) of total serum iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fed condition

  5. Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Capsule

    Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg ferric maltol capsule

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose on both PK days

  6. Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Capsule

    Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30 mg ferric maltol capsule

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in both PK days

  7. Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Suspension

    Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose on both PK days

  8. Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Suspension

    Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in both PK days

Secondary outcomes

  1. PK Analysis of Total Serum Iron Concentration; AUCinf in Fasted and Fed Conditions

    Descriptive statistics of total serum iron concentration; Area Under the Curve (AUCinf) by formulation (suspension or capsule) and condition (fed and fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  2. PK Analysis of Baseline Corrected Serum Iron Concentration; Cmax in Fasted and Fed Conditions

    Descriptive statistics of baseline corrected serum iron concentration; Maximum Concentration (Cmax), by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  3. PK Analysis of Baseline Corrected Serum Iron Concentration; AUClast in Fasted and Fed Conditions

    Descriptive statistics of baseline corrected serum iron concentration; area under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  4. PK Analysis of Baseline Corrected Serum Iron Concentration; AUCinf in Fasted and Fed Conditions

    Descriptive statistics of baseline corrected serum iron concentration; Area Under the Curve from 0-infinity by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  5. PK Analysis of Maltol Glucuronide; Cmax in Fasted and Fed Conditions

    Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol glucuronide by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  6. PK Analysis of Maltol Glucuronide; AUClast in Fasted and Fed Conditions

    Descriptive statistics of maltol glucuronide; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  7. PK Analysis of Maltol; Cmax in Fasted and Fed Conditions

    Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  8. PK Analysis of Maltol; AUClast in Fasted and Fed Conditions

    Descriptive statistics of maltol; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  9. PK Analysis of TSAT; Cmax in Fasted and Fed Conditions

    Descriptive statistics of Maximum Concentration (Cmax) of transferrin saturation by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  10. PK Analysis of TSAT; AUClast in Fasted and Fed Conditions

    Descriptive statistics of transferrin saturation; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  11. PK Analysis of TIBC; Cmax in Fasted and Fed Conditions

    Descriptive statistics of Maximum Concentration (Cmax) of Total Iron Binding Capacity (TIBC) by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  12. PK Analysis of TIBC; AUClast in Fasted and Fed Conditions

    Descriptive statistics of Total Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  13. Summary of Serious Adverse Events

    Descriptive statistics of Serious Adverse Events by formulation (suspension or capsule) and condition (fed and fasted)

    Time frame: up to 2 weeks following last dose

  14. PK Analysis of UIBC; Cmax in Fasted and Fed Conditions

    Descriptive statistics of Maximum Concentration (Cmax) of Unsaturated Iron Binding Capacity (UIBC) by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  15. PK Analysis of UIBC; AUClast in Fasted and Fed Conditions

    Descriptive statistics of Unsaturated Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1,1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  16. PK Analysis of Transferrin; Cmax in Fasted and Fed Conditions

    Descriptive statistics of transferrin; Maximum concentration (Cmax) from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  17. PK Analysis of Transferrin; AUClast in Fasted and Fed Conditions

    Descriptive statistics of transferrin; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

    Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

  18. Treatment-Emergent Adverse Events

    Treatment-Emergent Adverse Events from Day 1 to Day 22 (Study completion)

    Time frame: From first dose of ferric maltol on Day 1 to study completion

  19. TEAE Leading to Premature Discontinuation of Study Drug/PK Assessments

    TEAE leading to premature discontinuation of study drug/PK assessments from Day 1 to study completion

    Time frame: From first dose of ferric maltol on Day 1 to study completion

  20. Vital Signs - Blood Pressure, Change From Day 1 to Day 8

    Descriptive statistics for changes in blood pressure from Screening to Day 8

    Time frame: Screening to Day 8

  21. Vital Signs - Heart Rate, Change From Day 1 to Day 7

    Descriptive statistics for changes in heart rate from Screening to Day 7

    Time frame: Screening to Day 7

  22. Summary of Received Concomitant Medication by Formulation

    Number of participants having received concomitant medications by formulation (suspension or capsule)

    Time frame: Day 1 to Day 8 (24 hrs post-dose of last dosing)

07

Results

Posted Aug 24, 2025

Participant flow

32 subjects recruited. 8 subjects randomised to each sequence.

Participant flow — Overall Study
MilestoneFerric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence D
Started8888
Completed8888
Not completed0000

Outcome measures

PrimaryRatio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition

Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension.

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fasted condition
Reported as:
Geometric least squares mean · ratio
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition
ratioFerric Maltol Capsule and Ferric Maltol Suspension in a Fasted Condition
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition69.94 (61.75 to 79.23)
PrimaryRatio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition

Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fed condition
Reported as:
Geometric least squares mean · ratio
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition
ratioFerric Maltol Capsule Fed and Ferric Maltol Suspension Fed
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition99.11 (87.50 to 112.27)
PrimaryRatio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fasted Condition

Ratio of area under the curve (AUClast) of total serum iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fasted condition
Reported as:
Geometric least squares mean · ratio
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fasted Condition
ratioFerric Maltol Capsule Fasted and Ferric Maltol Suspension Fasted
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fasted Condition77.54 (70.38 to 85.42)
PrimaryRatio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fed Condition

Ratio of area under the curve (AUClast) of total serum iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fed condition
Reported as:
Geometric least squares mean · ratio
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fed Condition
ratioFerric Maltol Capsule Fed and Ferric Maltol Suspension Fed
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fed Condition96.99 (88.04 to 106.86)
PrimaryRatio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Capsule

Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg ferric maltol capsule

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose on both PK days
Reported as:
Geometric least squares mean · ratio
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Capsule
ratioFerric Maltol Capsule in Fed vs. Fasted Condition
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Capsule147.27 (130.01 to 166.81)
PrimaryRatio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Capsule

Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30 mg ferric maltol capsule

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in both PK days
Reported as:
Geometric least squares mean · ratio
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Capsule
ratioFerric Maltol Capsule in Fed vs. Fasted Condition
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Capsule134.25 (121.86 to 147.91)
PrimaryRatio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Suspension

Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose on both PK days
Reported as:
Geometric least squares mean · ratio
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Suspension
ratioFerric Maltol Suspension in Fed vs Fasted Condition
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Suspension103.93 (91.75 to 117.72)
PrimaryRatio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Suspension

Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in both PK days
Reported as:
Geometric least squares mean · ratio
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Suspension
ratioFerric Maltol Suspension in Fasted vs Fed Condition
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Suspension107.32 (97.41 to 118.24)
SecondaryPK Analysis of Total Serum Iron Concentration; AUCinf in Fasted and Fed Conditions

Descriptive statistics of total serum iron concentration; Area Under the Curve (AUCinf) by formulation (suspension or capsule) and condition (fed and fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of Total Serum Iron Concentration; AUCinf in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Total Serum Iron Concentration; AUCinf in Fasted and Fed Conditions2922.46 ± 1052.463694.05 ± 1561.1383330.98 ± 2128.8613445.41 ± 2615.954
SecondaryPK Analysis of Baseline Corrected Serum Iron Concentration; Cmax in Fasted and Fed Conditions

Descriptive statistics of baseline corrected serum iron concentration; Maximum Concentration (Cmax), by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of Baseline Corrected Serum Iron Concentration; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Baseline Corrected Serum Iron Concentration; Cmax in Fasted and Fed Conditions44.469 ± 73.057289.938 ± 50.992740.219 ± 52.971533.250 ± 23.0637
SecondaryPK Analysis of Baseline Corrected Serum Iron Concentration; AUClast in Fasted and Fed Conditions

Descriptive statistics of baseline corrected serum iron concentration; area under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of Baseline Corrected Serum Iron Concentration; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Baseline Corrected Serum Iron Concentration; AUClast in Fasted and Fed Conditions56.150 ± 964.9572691.392 ± 791.86712.503 ± 889.0745-9.436 ± 693.2830
SecondaryPK Analysis of Baseline Corrected Serum Iron Concentration; AUCinf in Fasted and Fed Conditions

Descriptive statistics of baseline corrected serum iron concentration; Area Under the Curve from 0-infinity by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose

No measurements were reported for this outcome.

SecondaryPK Analysis of Maltol Glucuronide; Cmax in Fasted and Fed Conditions

Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol glucuronide by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of Maltol Glucuronide; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Maltol Glucuronide; Cmax in Fasted and Fed Conditions3579.063 ± 1668.21205126.250 ± 1996.07483597.500 ± 1776.43907685.0 ± 1920.3797
SecondaryPK Analysis of Maltol Glucuronide; AUClast in Fasted and Fed Conditions

Descriptive statistics of maltol glucuronide; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of Maltol Glucuronide; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Maltol Glucuronide; AUClast in Fasted and Fed Conditions7335.93 ± 2449.5309083.82 ± 2902.8637802.52 ± 2585.84810410.89 ± 2631.072
SecondaryPK Analysis of Maltol; Cmax in Fasted and Fed Conditions

Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of Maltol; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Maltol; Cmax in Fasted and Fed Conditions16.994 ± 18.542020.531 ± 16.071433.600 ± 37.050134.656 ± 25.2179
SecondaryPK Analysis of Maltol; AUClast in Fasted and Fed Conditions

Descriptive statistics of maltol; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of Maltol; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Maltol; AUClast in Fasted and Fed Conditions28.61 ± 21.92417.29 ± 15.27439.13 ± 44.52522.41 ± 16.879
SecondaryPK Analysis of TSAT; Cmax in Fasted and Fed Conditions

Descriptive statistics of Maximum Concentration (Cmax) of transferrin saturation by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of TSAT; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of TSAT; Cmax in Fasted and Fed Conditions32.750 ± 18.479343.031 ± 12.942830.344 ± 12.597030.188 ± 9.3892
SecondaryPK Analysis of TSAT; AUClast in Fasted and Fed Conditions

Descriptive statistics of transferrin saturation; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of TSAT; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of TSAT; AUClast in Fasted and Fed Conditions509.90 ± 201.915644.62 ± 176.724484.64 ± 153.990513.62 ± 193.642
SecondaryPK Analysis of TIBC; Cmax in Fasted and Fed Conditions

Descriptive statistics of Maximum Concentration (Cmax) of Total Iron Binding Capacity (TIBC) by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of TIBC; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of TIBC; Cmax in Fasted and Fed Conditions393.688 ± 50.5208394.781 ± 50.9913396.938 ± 73.3577394.656 ± 46.5310
SecondaryPK Analysis of TIBC; AUClast in Fasted and Fed Conditions

Descriptive statistics of Total Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of TIBC; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of TIBC; AUClast in Fasted and Fed Conditions8719.09 ± 1097.9818880.52 ± 1165.5478718.02 ± 1195.3358878.43 ± 1069.977
SecondarySummary of Serious Adverse Events

Descriptive statistics of Serious Adverse Events by formulation (suspension or capsule) and condition (fed and fasted)

Time frame:
up to 2 weeks following last dose
Reported as:
Count of participants · Participants
Summary of Serious Adverse Events
Participants30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
Summary of Serious Adverse Events0000
SecondaryPK Analysis of UIBC; Cmax in Fasted and Fed Conditions

Descriptive statistics of Maximum Concentration (Cmax) of Unsaturated Iron Binding Capacity (UIBC) by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of UIBC; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of UIBC; Cmax in Fasted and Fed Conditions329.750 ± 57.3298323.250 ± 59.0172331.250 ± 82.0668322.375 ± 55.7018
SecondaryPK Analysis of UIBC; AUClast in Fasted and Fed Conditions

Descriptive statistics of Unsaturated Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1,1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of UIBC; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of UIBC; AUClast in Fasted and Fed Conditions6836.84 ± 1303.7576432.85 ± 1052.5896939.53 ± 1159.2956978.71 ± 1182.131
SecondaryPK Analysis of Transferrin; Cmax in Fasted and Fed Conditions

Descriptive statistics of transferrin; Maximum concentration (Cmax) from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · ng/mL
PK Analysis of Transferrin; Cmax in Fasted and Fed Conditions
ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Transferrin; Cmax in Fasted and Fed Conditions304.063 ± 42.7332302.594 ± 44.5051300.688 ± 42.3316303.031 ± 40.1670
SecondaryPK Analysis of Transferrin; AUClast in Fasted and Fed Conditions

Descriptive statistics of transferrin; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)

Time frame:
Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
PK Analysis of Transferrin; AUClast in Fasted and Fed Conditions
h*ng/mL30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
PK Analysis of Transferrin; AUClast in Fasted and Fed Conditions6711.95 ± 965.6326774.38 ± 948.8656701.92 ± 980.5226837.00 ± 936.103
SecondaryTreatment-Emergent Adverse Events

Treatment-Emergent Adverse Events from Day 1 to Day 22 (Study completion)

Time frame:
From first dose of ferric maltol on Day 1 to study completion
Reported as:
Count of participants · Participants
Treatment-Emergent Adverse Events
Participants30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
Treatment-Emergent Adverse Events0233
SecondaryTEAE Leading to Premature Discontinuation of Study Drug/PK Assessments

TEAE leading to premature discontinuation of study drug/PK assessments from Day 1 to study completion

Time frame:
From first dose of ferric maltol on Day 1 to study completion
Reported as:
Count of participants · Participants
TEAE Leading to Premature Discontinuation of Study Drug/PK Assessments
Participants30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
TEAE Leading to Premature Discontinuation of Study Drug/PK Assessments0000
SecondaryVital Signs - Blood Pressure, Change From Day 1 to Day 8

Descriptive statistics for changes in blood pressure from Screening to Day 8

Time frame:
Screening to Day 8
Reported as:
Mean · mmHg
Vital Signs - Blood Pressure, Change From Day 1 to Day 8
mmHgSequence ASequence BSequence CSequence D
Diastolic blood pressure-0.5 ± 3.02-0.3 ± 6.71-3.6 ± 7.58-2.4 ± 4.63
Systolic blood pressure-3.6 ± 6.25-4.6 ± 10.90-4.9 ± 14.59-0.1 ± 7.16
SecondaryVital Signs - Heart Rate, Change From Day 1 to Day 7

Descriptive statistics for changes in heart rate from Screening to Day 7

Time frame:
Screening to Day 7
Reported as:
Mean · beats/min
Vital Signs - Heart Rate, Change From Day 1 to Day 7
beats/minSequence ASequence BSequence CSequence D
Vital Signs - Heart Rate, Change From Day 1 to Day 7-0.8 ± 10.268.1 ± 8.6911.1 ± 11.233.1 ± 6.13
SecondarySummary of Received Concomitant Medication by Formulation

Number of participants having received concomitant medications by formulation (suspension or capsule)

Time frame:
Day 1 to Day 8 (24 hrs post-dose of last dosing)
Reported as:
Number · participants
Summary of Received Concomitant Medication by Formulation
participants30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
Summary of Received Concomitant Medication by Formulation2222

Adverse events

Collected over 8 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 mg Ferric Maltol Capsule in a Fed Condition0/32 (0%)0/32 (0%)0/32 (0%)
30 mg Ferric Maltol Capsule in a Fasted Condition0/32 (0%)0/32 (0%)2/32 (6.3%)
30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition0/32 (0%)0/32 (0%)3/32 (9.4%)
30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition0/32 (0%)0/32 (0%)3/32 (9.4%)
Most frequent other events
Most frequent other events
Event30 mg Ferric Maltol Capsule in a Fed Condition30 mg Ferric Maltol Capsule in a Fasted Condition30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition
HeadacheNervous system disorders0/321/320/322/32
Vessel puncture site painGeneral disorders0/321/321/320/32
RhinalgiaRespiratory, thoracic and mediastinal disorders0/320/321/320/32
PruritusSkin and subcutaneous tissue disorders0/320/321/320/32
Hypoaesthesia oralGastrointestinal disorders0/320/320/321/32

Baseline characteristics

Overall demographic and baseline characteristics of the randomised population. The Randomized population is defined as all subjects who are randomized. The FAS is defined as all subjects who have had at least one dose of study drug and who have at least one evaluable post-dose PK sample.

Age, Categorical
Age, Categorical(Participants)Ferric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence DTotal
<=18 years00000
Between 18 and 65 years888832
>=65 years00000
Age, Continuous
Age, Continuous(years)Ferric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence DTotal
Mean36.6 ± 9.3334.00 ± 11.0533.6 ± 6.4440.5 ± 8.8236.18 ± 8.90
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence DTotal
Female334515
Male554317
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ferric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence DTotal
Hispanic or Latino00123
Not Hispanic or Latino887629
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ferric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence DTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American865524
White02338
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Ferric Maltol Sequence AFerric Maltol Sequence BFerric Maltol Sequence CFerric Maltol Sequence DTotal
United States888832
08

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 1 month.

Results were first posted in Aug 2025, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2020
First posted
Nov 12, 2020
StartActual
Sep 28, 2020
Primary completionActual
Nov 13, 2020
CompletionActual
Nov 13, 2020
Results first posted
Aug 24, 2025
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04626414
Lead sponsor
Shield Therapeutics
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Sep 28, 2020
Primary completion
Nov 13, 2020
Completion
Nov 13, 2020
Results posted
Aug 24, 2025
Last update
Aug 24, 2025

Study contacts

Jackie Mitchell, DPhil
study director · Shield Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion